The Ghana Health Service (GHS) in the Upper East Region is set to administer medication to 164,525 residents as part of efforts to prevent and control onchocerciasis, commonly known as river blindness.
The second phase of the 2026 Mass Drug Administration (MDA) campaign is scheduled to run from November 15 to 28, targeting communities in 14 sub-districts across Bawku West, Builsa South, Kassena-Nankana West and Tempane.
Speaking at a media engagement in Bolgatanga, the Upper East Regional Director of Health Services, Dr Braimah Baba Abubakari, said trained health personnel and community volunteers would distribute ivermectin tablets through a house-to-house exercise.
He disclosed that an estimated 205,656 people in the region were vulnerable to the disease, making widespread participation in the treatment campaign critical to reducing transmission and preventing complications, including blindness.
Onchocerciasis is caused by a parasitic worm transmitted through repeated bites from infected blackflies, which commonly breed around fast-flowing rivers and streams. The infection can result in persistent itching, skin changes and, in severe cases, permanent loss of sight.
Dr Abubakari explained that certain groups would be excluded from the medication for safety reasons. These include pregnant women, children below 90 centimetres in height, breastfeeding mothers whose babies are less than one week old, and individuals who are severely ill.
He encouraged eligible residents to take advantage of the exercise and advised anyone who experiences an adverse reaction after taking the medication to contact a Community-Based Drug Distributor or visit the nearest health facility.
At the national level, the campaign is expected to reach approximately 6.3 million people across 86 districts in 15 regions.
The Regional Health Director further called on traditional and religious leaders, Assembly Members and the media to intensify public education and help mobilise residents to participate in the exercise.
The campaign is being implemented with support from the National Neglected Tropical Diseases Programme, with NOORDUBAI serving as its principal sponsor.










